This trial is evaluating whether VOR33 will improve 1 primary outcome and 10 secondary outcomes in patients with Leukemia, Myeloid, Acute. Measurement will happen over the course of Up to approximately 28 days.
This trial requires 18 total participants across 3 different treatment groups
This trial involves 3 different treatments. VOR33 is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"The cause of acute leukemia, myeloid, is mostly unknown. But, the likelihood of leukemia, myeloid, acute progressing into chronic leukemia is affected by several factors, including patient age, sex and race, exposure to ionizing radiation and other exogenous substances (drugs or infection), and the particular type of leukemia. The risk is greater for acute lymphocytic leukemia compared to acute myelogenous leukemia. Exposure to ionizing radiation for cancer treatment and leukemia survivors have increased the risk of developing leukemia, myeloid, acute. This is due to the risk of developing leukemia as a result of mutation of genes responsible for DNA repair and the cellular pathways to repair DNA." - Anonymous Online Contributor
"Symptoms of leukemia, myeloid, acute will range from vague discomfort to life-threatening. Symptoms may arise in any of the body systems. Symptoms are quite variable and can resemble that of flu, cold or any other infection. The causes of symptoms are diverse and include the bone marrow and blood. Diagnosis is best accomplished through an evaluation by a physician. It is important to recognize the typical symptomatology of leukemia, myeloid, acute." - Anonymous Online Contributor
"Chronic phase chronic myeloid leukemia and chronic phase acute myeloid leukemia are relatively curable when the karyotypic abnormality remains in < 15% of the nuclei, thus do not have the potential to be cured if the leukemia was refractory for a prolonged period of time." - Anonymous Online Contributor
"This national count is consistent with an estimated 2,600 new cases of leukemia, myeloid, acute in the next 5 years (2,620 in the last 5 yr). In addition to other cancer rates, an accurate 5-year count of the leukemias (acute lymphoblastic, acute myeloid, chronic lymphocytic, and multiple myeloma), and all myeloproliferative lymphoproliferative disorders (Chronic myelogenous, idiopathic, and primary myelofibrosis) should be kept." - Anonymous Online Contributor
"Treatment for leukemia, myeloid, acute is mostly chemotherapy or surgery. This article also discusses the treatment of children with leukemia with chemotherapy using growth hormone for growth problems, and with bone marrow transplants if the underlying leukemia is myelogenous. Although chemotherapy destroys the bone marrow, bone marrow transplantation can help the patient. Treatment with astemizole to reduce side effects from chemotherapy is also common." - Anonymous Online Contributor
"There are 20 identifiable variants, but most types can be diagnosed using clinical information and routine laboratory testing. The variants identified here comprise most cases of all-trans-retinoic acid (ATRA)-resistant acute myeloid leukemia and are potentially treatable with fludarabine, an analog of ATRA. We will not propose for these to be recognized as a separate "type." There are, however, many other variants, and some of these also could be treated in this way but this would have to be validated in studies in larger patient populations." - Anonymous Online Contributor
"Vor33 is toxic in mice. The major side effects of vor33 in mice are lethality and renal cytopenia. The major side effects of vor33 in monkeys are reversible, dose-dependent renal toxicity and hepatic toxicity." - Anonymous Online Contributor
"There is less discussion about the overall efficacy of the vor33 gene therapy for the treatment of non-LMSC cancers than for LMSC malignancies. Clinicians will likely find clinical trials for specific cancers in the upcoming years." - Anonymous Online Contributor
"It is common to hear people say 'there needs to be a breakthrough in cancer research to treat leukemia, myeloid, acute' and that such research doesn't happen very often. On that note, we discuss some significant recent discoveries relevant to hematological malignancies. As for the other types of malignancies we are discussing in this article, we don't intend to focus on such discoveries; rather, we expect that such discoveries will be mentioned and explained when relevant. In the future we expect other discoveries relevant to hematological malignancies, of which there many." - Anonymous Online Contributor
"Patients with acute leukemias (AL) and MDS and some patients with CLL who had vor33 used in combination with other treatments were responsive. The treatment schedules for patients used more than one treatment or used vor33 in combination with vor33 are currently being evaluated." - Anonymous Online Contributor
"Data from a recent study suggest that the transcriptional profile of myeloid and lymphoid progenitor cells is differentially regulated by Vor33 and that Vor33 may target certain aspects of human myeloid and lymphoid development by altering the transcriptional activity of its targets; Vor33 may thus exert its proliferative effects on myeloid and lymphoid cells in ways that would not be anticipated in the absence of its target, which is not a member of the Vor family." - Anonymous Online Contributor
"While there is currently no cure available for leukemia, [power], a health information website for [people with leukemia, myeloid, acute (LMWE)] can help you find recent clinical trial information on treatments for these conditions. Clinical trials are often used to test whether a treatments or drug helps improve outcomes for those with LMWE, even if they do not cure the condition. While LMWE treatments exist, [research] can help you choose the treatment that will best meet your individual needs." - Anonymous Online Contributor